Amgen Inc.

Joshua Taygerly

Sean P Brown

Yunxiao Li

Xianghong Wang

Marc Vimolratana

Kexue Li

Mike Elias Lizarzaburu

Todd J Kohn

Manuel Zancanella

Matthew R Kaller

Liusheng Zhu

Ana Elena Minatti

Brian Alan Lanman

Ming Yu

Alexander J Pickrell

Jonathan Dante Low

Paul E Harrington

Markian Myroslaw Stec

Ana Zurisadai Gonzalez Buenrostro

Zhihong Li

Nick A Paras

Kate Ashton

Brian Stuart Lucas

Julio Cesar Medina

Jonathan B Houze

Xuelei Yan

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Alan C Cheng

Mario G Cardozo

Jason A Duquette

Yingcai Wang

Michael R Degraffenreid

Jiasheng Fu

Xian Yun Jiao

Michael W Gribble, Jr

Jiang Zhu

David Karl Bedke

Mike Elias Lizazaburu

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibits MCL-1 protein

Compounds that inhibit Mcl-1 protein

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Growing community of inventors

San Francisco, CA, United States of America

Joshua Taygerly